Novartis Ag (NVS) Income from Discontinued Operations (2013 - 2023)
Novartis Ag (NVS) posted Income from Discontinued Operations of 18000000.0 for Q4 2023, up 82.18% sequentially from 101000000.0 in Q4 2019.
Novartis Ag (NVS) Income from Discontinued Operations (2013 - 2023) Analysis & Trends
Novartis Ag has reported Income from Discontinued Operations for 5 years, with the latest figure at 18000000.0 in Q4 2023.
- Quarterly Income from Discontinued Operations changed N/A year-over-year to 18000000.0 in Q4 2023, while the trailing twelve-month figure through Dec 2023 was 21000000.0 (changed N/A YoY) and the FY2023 annual result came in at 422000000.0, down 53.42% from the prior year.
- Income from Discontinued Operations improved to 18000000.0 in Q4 2023 per NVS's latest filing, from 101000000.0 in the prior quarter.
- Over five years, Income from Discontinued Operations peaked at 18000000.0 in Q4 2023 and troughed at 101000000.0 in Q4 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Discontinued) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | - |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | - |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | - |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | - |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | - |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 8.00 Mn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | - |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | -18.00 Mn |
| Dec 31, 2019 | -101.00 Mn |
| Dec 31, 2018 | 98.00 Mn |
| Sep 30, 2018 | -258.00 Mn |
| Jun 30, 2018 | 40.00 Mn |
| Sep 30, 2014 | 138.00 |
| Sep 30, 2013 | 105.00 |